These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34735925)

  • 1. Biological implications of the immune factors in the tumour microenvironment of oral cancer.
    Shetty SS; Padam KSR; Hunter KD; Kudva A; Radhakrishnan R
    Arch Oral Biol; 2022 Jan; 133():105294. PubMed ID: 34735925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor microenvironment and immunotherapy of oral cancer.
    Liu C; Wang M; Zhang H; Li C; Zhang T; Liu H; Zhu S; Chen J
    Eur J Med Res; 2022 Oct; 27(1):198. PubMed ID: 36209263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of tumour microenvironment in the progression and development of oral cancer.
    Mughees M; Sengupta A; Khowal S; Wajid S
    Mol Biol Rep; 2021 Feb; 48(2):1773-1786. PubMed ID: 33492572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies.
    Fanelli GN; Grassini D; Ortenzi V; Pasqualetti F; Montemurro N; Perrini P; Naccarato AG; Scatena C
    Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33804731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic manipulation of the tumour immune microenvironment.
    Wan M; Ding Y; Li Z; Wang X; Xu M
    Immunology; 2022 Mar; 165(3):290-300. PubMed ID: 34962655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
    Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
    Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumour microenvironment and implications for cancer immunotherapy.
    Petrulio CA; Kim-Schulze S; Kaufman HL
    Expert Opin Biol Ther; 2006 Jul; 6(7):671-84. PubMed ID: 16805707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.
    Nagarsheth N; Wicha MS; Zou W
    Nat Rev Immunol; 2017 Sep; 17(9):559-572. PubMed ID: 28555670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing.
    Bai R; Cui J
    Front Immunol; 2022; 13():890166. PubMed ID: 35833121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the tumour microenvironment in immunotherapy.
    Gasser S; Lim LHK; Cheung FSG
    Endocr Relat Cancer; 2017 Dec; 24(12):T283-T295. PubMed ID: 28754821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?
    O'Malley G; Heijltjes M; Houston AM; Rani S; Ritter T; Egan LJ; Ryan AE
    Oncotarget; 2016 Sep; 7(37):60752-60774. PubMed ID: 27542276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decoding the influence of the immune system and immunotherapy targets on carcinomas: A hidden prism in oral cancer therapy.
    Dhara V; Shetty SS; de Arruda JAA; Silva TA; Russo RC; Shetty NJ; Pidaparthi M; Wollenberg B; Rao VUS; Gopinath TPS
    Dis Mon; 2023 Jan; 69(1):101353. PubMed ID: 35311656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extranodal extension in oral cancer: A role for the nodal microenvironment?
    Pilborough AE; Lambert DW; Khurram SA
    J Oral Pathol Med; 2019 Nov; 48(10):863-870. PubMed ID: 31087397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unravelling Tumour Microenvironment in Melanoma at Single-Cell Level and Challenges to Checkpoint Immunotherapy.
    Bai X; Quek C
    Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hypoxic tumour microenvironment: A safe haven for immunosuppressive cells and a therapeutic barrier to overcome.
    Chang WH; Lai AG
    Cancer Lett; 2020 Sep; 487():34-44. PubMed ID: 32470490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression.
    Armitage JD; Newnes HV; McDonnell A; Bosco A; Waithman J
    Cells; 2021 Jan; 10(1):. PubMed ID: 33401460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
    Flower KJ; Ghaem-Maghami S; Brown R
    Curr Cancer Drug Targets; 2018; 18(1):5-15. PubMed ID: 28176650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of pancreatic cancer.
    Sunami Y; Kleeff J
    Prog Mol Biol Transl Sci; 2019; 164():189-216. PubMed ID: 31383405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated immune cells and their modulation by melatonin.
    Hekmatirad S; Moloudizargari M; Fallah M; Rahimi A; Poortahmasebi V; Asghari MH
    Immunopharmacol Immunotoxicol; 2023 Dec; 45(6):788-801. PubMed ID: 37489565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural products and their derivatives as immune check point inhibitors: Targeting cytokine/chemokine signalling in cancer.
    Gupta M; Chandan K; Sarwat M
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):214-232. PubMed ID: 35772610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.